LL-37 Evidence Guide
Evidence for LL-37 is too preliminary to support a research protocol with confidence. Human data is limited to small wound-healing and topical studies; no Phase 2/3 trials exist for systemic use. Of the Immune Support compounds, thymosin alpha-1 (thymosin-alpha-1) has a substantially stronger evidence base as a starting point.
Our Take
Evidence for LL-37 is too preliminary to support a research protocol with confidence. Human data is limited to small wound-healing and topical studies; no Phase 2/3 trials exist for systemic use. Of the Immune Support compounds, thymosin alpha-1 (thymosin-alpha-1) has a substantially stronger evidence base as a starting point.
- Best for
- Antimicrobial peptide research, wound healing (topical), innate immunity mechanistic studies
- Evidence grade
- Level C
- Confidence
- Low
- Starting point
- No established systemic human protocol - evidence is too early-stage
Benefits and Evidence
- Antimicrobial Activity: Level B, mostly non-human evidence - Extensive in vitro and animal evidence for broad-spectrum antimicrobial activity. Effective against antibiotic-resistant bacteria including MRSA.
- Immune Modulation: Level C, mostly non-human evidence - Preclinical data demonstrates significant immunomodulatory properties, balancing pro- and anti-inflammatory responses.
- Wound Healing Support: Level C, mostly non-human evidence - Heilborn et al. (2003, J Invest Dermatol) found reduced LL-37 in chronic venous ulcers vs. acute wounds; Ramos et al. (2011, J Clin Invest) showed LL-37 at 10 ug/wound promoted angiogenesis and re-epithelialization in murine wound models.
- Anti-Biofilm: Level C, mostly non-human evidence - In vitro studies consistently demonstrate disruption of established biofilms and prevention of new biofilm formation at sub-inhibitory concentrations.
Side Effects and Warnings
- Possible injection site reactions
- May cause local inflammation at high concentrations
- Hemolytic activity at very high concentrations
- Limited human safety data
- Early-stage research peptide only
- Can be pro-inflammatory at high concentrations
- May exacerbate autoimmune conditions
- Rapidly degraded in vivo, limiting therapeutic utility
Research Dosage References
- <strong>Subcutaneous injection</strong> - 50-100 mcg - Once daily - Research dosing. Limited human pharmacokinetic data available.
- <strong>Topical</strong> - 0.1-1% solution - Once or twice daily - Applied to wound sites. Research use for infected or chronic wounds.
Mechanism of Action
LL-37 has multifaceted immune functions: 1. Direct antimicrobial activity: Forms pores in bacterial membranes, disrupting cell integrity. Active against gram-positive, gram-negative bacteria, and fungi. 2. Anti-biofilm: Disrupts bacterial biofilm formation, which is resistant to conventional antibiotics. 3. Immunomodulation: Recruits immune cells to sites of infection, modulates inflammatory cytokine production. 4. Wound healing: Promotes epithelial cell migration and proliferation, enhances angiogenesis at wound sites. 5. Antiviral activity: Disrupts viral envelopes and inhibits viral replication. Active against enveloped viruses. 6. Vitamin D connection: Expression is upregulated by vitamin D, linking vitamin D status to innate immune function.
Legal Status
LL-37 is a research peptide not approved for clinical use. Available for research purposes. Not a controlled substance. Active area of pharmaceutical development with modified analogs in clinical trials.
Primary Sources
- LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Commun Integr Biol, 2012.
- Antimicrobial peptides: from antibiotic adjuvants to antibiotic alternatives. Adv Drug Deliv Rev, 2019.